EcoDrugPlus

Mitogen-Activated Protein Kinase 1

Ensembl ID : ENSCAFG00020015099
Gene Symbol: MAPK1
3 Cross references
214 Possible Orthologues:

Mitogen-Activated Protein Kinase 10

Ensembl ID : ENSCAFG00020009946
Gene Symbol: MAPK10
3 Cross references
222 Possible Orthologues:

Mitogen-Activated Protein Kinase 11

Ensembl ID : ENSCAFG00020008293
Gene Symbol: MAPK11
3 Cross references
201 Possible Orthologues:

Mitogen-Activated Protein Kinase 14

Ensembl ID : ENSCAFG00020007162
Gene Symbol: MAPK14
3 Cross references
293 Possible Orthologues:

Mitogen-Activated Protein Kinase 3

Ensembl ID : ENSCAFG00020017614
Gene Symbol: MAPK3
2 Cross references
194 Possible Orthologues:

Mitogen-Activated Protein Kinase 8

Ensembl ID : ENSCAFG00020025053
Gene Symbol: MAPK8
3 Cross references
292 Possible Orthologues:

Mitogen-Activated Protein Kinase 9

Ensembl ID : ENSCAFG00020002569
Gene Symbol: MAPK9
3 Cross references
219 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase 1

Ensembl ID : ENSCAFG00020008392
Gene Symbol: MAP2K1
3 Cross references
211 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase 2

Ensembl ID : ENSCAFG00020018484
Gene Symbol: MAP2K2
3 Cross references
269 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 1

Ensembl ID : ENSCAFG00020023953
Gene Symbol: MAP3K1
3 Cross references
160 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 10

Ensembl ID : ENSCAFG00020015597
Gene Symbol: MAP3K10
3 Cross references
186 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 11

Ensembl ID : ENSCAFG00020015052
Gene Symbol: MAP3K11
3 Cross references
184 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).